报告 118例不能手术ⅢB 期非小细胞肺癌的远期疗效 .所有病例均给CAP或MVP方案化疗 ,97例行根治性放疗 .全组病例 1a ,3a ,5a生存率分别为 5 3 5 % ,19 5 % ,8 5 % .鳞癌 3a及 5a生存率高于腺癌 ,差异有显著性 (P <0 0 5 ) .T4 N0 M0 3a及 5a生存率高于T3 N3 M0 ,T4 N1～ 2 M0 ,T4 N3 M0 ,差异有显著性(P <0 0 5～ 0 0 1) .CAP ,MVP两种化疗的 3a及 5a生存率之间差异无显著性 The long-term efficacy of 118 patients with stage IIIB non-small cell lung cancer was not reported. All patients were treated with CAP or MVP regimen, and 97 patients underwent radical radiotherapy. The overall survival rates for 1a, 3a, and 5a were 535%. 19 5 % ,8 5 %. The survival rate of squamous cell carcinoma 3a and 5a was higher than that of adenocarcinoma. The difference was significant (P <0 05). The survival rate of T4 N0 M0 3a and 5a was higher than that of T3 N3 M0, T4 N1 ~ 2 M0, T4 N3 M0, the difference was significant (P <0 0 5 ~ 0 0 1). CAP, MVP two kinds of chemotherapy 3a and 5a survival difference was not significant